SCHEMBL1775987

SCHEMBL1775987

Cc1ccc(NS(=O)(=O)c2c(Br)sc3ccnc(N4CCN(C)CC4)c23)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HTR6 P50406 4/20 0.39
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2A P28223 1/20 0.39
HTR7 P34969 1/20 0.39
NMT1 P30419 1/20 0.38
RAB9A P51151 1/20 0.38
MAPT P10636 3/20 0.37
USP2 O75604 1/20 0.37
POLB P06746 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1774418 0.99 HTT (0.39) HTTSMN1; SMN2KDM4EHTR6HTR1A
SCHEMBL1775869 0.91 LMNA (0.39) SMN1; SMN2KDM4EHTR6HTR1AHTR1D
Hydrochloric Acid SCHEMBL1776644 0.90 LMNA (0.39) SMN1; SMN2KDM4EHTR6HTR1AHTR1D
SCHEMBL1775387 0.82 HRH4 (0.39) HTTHTR2AMAPTALDH1A1
SCHEMBL1775433 0.80 HTR6 (0.40) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL1775083 0.80 MAPT (0.38) HTTSMN1; SMN2KDM4EHTR6HTR1A
Hydrochloric Acid SCHEMBL1775132 0.79 POLB (0.39) HTTSMN1; SMN2KDM4EHTR6HTR1A
SCHEMBL1775937 0.79 CDK1 (0.42) HTTSMN1; SMN2KDM4EMAPTUSP2
SCHEMBL1775441 0.78 HTR6 (0.45) HTTSMN1; SMN2KDM4EHTR6HTR1A
Hydrochloric Acid SCHEMBL1775491 0.77 HTR6 (0.45) HTTSMN1; SMN2KDM4EHTR6HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943639-B2 Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss PROXIMAGEN LIMITED (GB) 2011-05-17 US claimed
US-7943639-B2 Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss PROXIMAGEN LIMITED (GB) 2011-05-17 US disclosed
EP-1897881-A2 Compounds useful for the treatment of obesity, type II diabetes and CNS disorders Biovitrum AB (publ) (SE) 2008-03-12 EP disclosed
EP-1513828-A1 NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS Biovitrum AB (SE) 2005-03-16 EP disclosed
US-20040024210-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2004-02-05 US disclosed
WO-2004000828-A1 NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS BIOVITRUM AB (SE) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024210-A1 New compounds SULT1E1, SULT2A1, SULT1A1 HTT 2558/4885SMN1; SMN2 960/4885KDM4E 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.